miR Scientific Presents Groundbreaking Data on the Exceptional Accuracy of its Prostate Cancer Liquid-Biopsy Test
miR Scientific abstract presented at the American Urological Association's 2021 Annual Meeting
Breakthrough novel liquid-biopsy test shows high sensitivity for the presence or absence of any prostate cancer, and low vs. intermediate vs. high-risk disease
New study reveals high correspondence in negative predictive values of standalone non-invasive liquid-biopsy test
20 Sep, 2021, 08:30 ET
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the data on more than 1,400 patients published in The Journal of Urology in September 2020.
When comparing the results of the miR Sentinel® Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of clinically significant cancer. This 93% sensitivity of the miR Sentinel Prostate Cancer Test sets a new bar for detecting and classifying prostate cancer. The data further demonstrate the strong negative predictive value of the miR Sentinel Prostate Cancer Test with results showing the test correctly identified 96% (371/387) of men as having non-clinically significant cancer.
"Our mission to inclusively transform cancer management is further validated in this prospective study, demonstrating that the miR Sentinel Prostate Cancer Test is able to provide an accurate non-invasive means to identify the presence or absence of any prostate cancer and classify the molecular risk of disease becoming metastatic, and thereby lethal, prior to biopsy" says Sam Salman, Chairman and CEO of miR Scientific. "We believe that the accuracy, accessibility, and non-invasive features of our award-winning technology will impact the lives of millions of men and forever positively evolve the standard of care for urological cancers."
Cross-Validation Study Results
The data reported in this late-breaking abstract and presented by Laurence Klotz, MD, FRCSC at the AUA, is based on a study of 763 men over 45 years old, eligible for their first core needle biopsy. Pathology based on the core needle biopsy showed 354 (46%) were biopsy negative and 409 (54%) were biopsy positive. Of those 409 men found to have pathologic evidence of disease, 189 (25%) were classified as Grade Group 1 (GG1) representing non-clinically significant cancer, and 220 were classified as Grade Group 2 (GG2) or higher representing clinically significant cancer.
With just a urine liquid biopsy, the miR Sentinel Prostate Cancer Test identified 204 men with clinically significant cancer (intermediate or high risk), demonstrating 93% sensitivity (204/220) with the core needle biopsy. When evaluating men with non-clinically significant cancer, the miR Sentinel Prostate Cancer Test identified 371 out of 387 men, delivering 96% (371/387) sensitivity.
The data further examined the apparent false positive rate for clinically significant cancer by analyzing the sub-set of men who underwent both systematic biopsy and MRI-fusion biopsy, and who were negative on systematic biopsy. The data demonstrates >95% concordance been the positive MRI-guided biopsy and the miR Sentinel® Prostate Cancer Test, indicating that the discordance between systematic biopsy results and the miR Sentinel Prostate Cancer Test are largely attributable to false negatives of biopsy.
Laurence Klotz, MD, FRCSC, Professor of Surgery at the University of Toronto, and Chief Medical Officer of miR Scientific LLC, said, "The key features of the test are the very high negative predictive value and the very high accuracy [in] identifying cancer. In addition to its quick turnaround, the test is highly scalable: the company will be able to perform a very large number of these tests right away."
Innovative Urine-based Liquid Biopsy
The miR Sentinel Prostate Cancer Test, which already received the Breakthrough Device Designation by the FDA, is a non-invasive molecular test based on the analysis of small non-coding RNAs (sncRNA) isolated from non-DRE urinary exosomes. It provides an innovative method to analyze sncRNAs derived from a simple, non-invasive urine specimen from age-eligible men. Using only the expression dynamics of these sncRNAs, a proprietary Statistical Classification Algorithm derives scores that classify patients according to the likelihood of being in the following four possible groups: no molecular evidence of prostate cancer; low-risk; intermediate-risk; or high-risk prostate cancer.
The miR Sentinel Prostate Cancer Test is expected to be commercially available in the United States and Puerto Rico at the end of this year.
About miR Scientific
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform powers the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from non-DRE urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.
For more information:
SOURCE miR Scientific, LLC
Share this article